CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions

Advanced Solid TumorBreast Cancer

Interventions

DRUG

CFI-402257

Oral once daily in 28 day cycles

DRUG

Fulvestrant

500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle

Trial Locations (4)

Virginia Cancer Specialist, Fairfax

The Ohio State University Comprehensive Cancer Center, Columbus

START San Antonio, San Antonio

START - Mountain Region, West Valley City

All Listed Sponsors

lead

Treadwell Therapeutics, Inc

INDUSTRY